PDS Biotechnology Corporation

As of June 30, 2026, PDS Biotechnology Corp. carries a market capitalization of 42.95M, placing it among publicly traded companies globally. Its enterprise value stands at 41.87M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

PDS Biotechnology Corp.'s next confirmed earnings release is scheduled for November 12, 2026.

As of June 30, 2026, PDS Biotechnology Corp. has 55.92M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, PDS Biotechnology Corp. maintains a current ratio of 0.57, meaning it holds 0.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -121.90, indicating conservative leverage, while an interest coverage ratio of -4.18 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -136.65, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 21.75, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, PDS Biotechnology Corp.'s stock has gained approximately 26.49% over the past 52 weeks. The 50-day moving average sits at 0.59, while the 200-day moving average is 0.71.

Over the twelve months ended June 30, 2026, PDS Biotechnology Corp. generated - - in revenue and converted that into -29.47M in net income, yielding earnings per share of -0.56. EBITDA reached -24.34M, while operating income came in at -24.36M.

As of June 30, 2026, PDS Biotechnology Corp. holds 4.90M in cash and equivalents against 3.82M in total debt, resulting in a net debt position of -1.11M. Total book value stands at -3.13M, with working capital of -4.67M providing operational flexibility.

PDS Biotechnology Corp. produced -14.69M in operating cash flow over the twelve months ended June 30, 2026. After subtracting - - in capital expenditures, free cash flow totaled -14.69M - equivalent to -0.28 per share.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -36.11: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 19.35, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to PDS Biotechnology Corp. shareholders.

PDS Biotechnology Corp.'s most recent stock split took place on March 18, 2019 with a 20:1 split ratio.

As of June 30, 2026, PDS Biotechnology Corp. has an Altman Z-Score of -45.93, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.